NEW YORK, March 6 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE Alternext US: MGT) and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, is pleased to announce it has launched ColonCAD API 4.0, the latest version of its computer-aided detection software, today at the European Congress of Radiology (ECR 2009) show in Vienna. The software is designed to assist radiologists in the detection of colorectal polyps in CT colonography image data. Version 4.0 includes a significant increase in the performance of the polyp detection algorithm, reducing the number of false positive CAD marks displayed for each patient case.
Dr David Burling, Consultant Gastrointestinal Radiologist and VC Program Director at St. Mark's Hospital, London, UK commented today, 'We welcome this latest improvement to Medicsight's ColonCAD product. CAD is now an integral part of our reading strategy in routine clinical practice. It improves interpretation accuracy and is complimentary to workflow.'
Internal testing on a dataset of 91 patient cases showed that the ColonCAD API 4.0 maintains the same high levels of sensitivity to the previous version but displays a 50% reduction in false positives, with the CAD now returning a mean of 6.5 false positive marks per patient case*. ColonCAD API 4.0 demonstrates the following sensitivity:
Size of Polyp Sensitivity
2mm-50mm 85%
6mm-9mm 90%
10mm+ (clinically significant) 92%+
The patient data used in this testing remained independent from the development of the CAD and have been endoscopically validated and reviewed by a panel of expert radiologists to determine the ground truth against which the CAD performance was assessed.
Allan Rowley, Chief Executive of Medicsight, commented, 'Previous research has shown Medicsight's ColonCAD significantly improves the performance of radiologists in the detection of polyps in CT colonography image data.
